Biomark Diagnostics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	0.06	0.15	0.16	0.15	0.04
Revenue Growth	-61.23%	-5.52%	6.34%	249.38%	-
Gross Profit	0.06	0.15	0.16	0.15	0.04
Selling, General & Admin	0.64	0.74	0.75	0.73	0.65
Research & Development	0.67	0.7	0.65	0.55	0.5
Operating Expenses	1.78	2.2	1.87	1.99	1.33
Operating Income	-1.72	-2.05	-1.71	-1.84	-1.28
Interest Expense	-0.06	-0.06	-0.06	-0.11	-0.04
Interest & Investment Income	0.05	0	0	0	-
Currency Exchange Gain (Loss)	-0.06	-0	0	-	-0
Other Non Operating Income (Expenses)	0.32	0.18	0.34	0.11	-0.13
EBT Excluding Unusual Items	-1.48	-1.93	-1.43	-1.84	-1.45
Pretax Income	-1.48	-1.93	-1.43	-1.84	-1.45
Net Income	-1.48	-1.93	-1.43	-1.84	-1.45
Net Income to Common	-1.48	-1.93	-1.43	-1.84	-1.45
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	105	91	85	83	78
Shares Outstanding (Diluted)	105	91	85	83	78
Shares Change	15.58%	6.67%	2.97%	6.22%	6.31%
EPS (Basic)	-0.01	-0.02	-0.02	-0.02	-0.02
EPS (Diluted)	-0.01	-0.02	-0.02	-0.02	-0.02
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-1.09	-1.1	-0.99	-0.92	-1.26
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.02
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-2877.96%	-1327.45%	-1046.96%	-1198.95%	-2922.50%
Profit Margin	-2470.76%	-1249.73%	-874.52%	-1200.21%	-3309.36%
Free Cash Flow Margin	-1828.20%	-711.12%	-604.65%	-599.20%	-2875.13%
EBITDA	-1.7	-2.03	-1.7	-1.83	-1.28
D&A For EBITDA	0.02	0.02	0.01	0.01	0.01
EBIT	-1.72	-2.05	-1.71	-1.84	-1.28